Clearside Biomedical (Clearside Biomedical) Cash And Cash Equivalents : $28.92 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Cash And Cash Equivalents?

Clearside Biomedical's quarterly cash and cash equivalents declined from Jun. 2023 ($35.01 Mil) to Sep. 2023 ($28.80 Mil) but then increased from Sep. 2023 ($28.80 Mil) to Dec. 2023 ($28.92 Mil).

Clearside Biomedical's annual cash and cash equivalents increased from Dec. 2021 ($30.44 Mil) to Dec. 2022 ($48.26 Mil) but then declined from Dec. 2022 ($48.26 Mil) to Dec. 2023 ($28.92 Mil).

Clearside Biomedical Cash And Cash Equivalents Historical Data

The historical data trend for Clearside Biomedical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Cash And Cash Equivalents Chart

Clearside Biomedical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

22.60

17.29

30.44

48.26

28.92

Clearside Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															48.26	41.42	35.01	28.80	28.92

Clearside Biomedical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Clearside Biomedical (NAS:CLSD) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Clearside Biomedical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical (Clearside Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

CLM:Germany CLM:Germany

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Executives

Charles A. Deignan	officer: Chief Financial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay	director	1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore	10 percent owner	5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp	director, 10 percent owner	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla	officer: Chief Medical Officer	C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Daniel H. White	director, officer: President and CEO	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond	officer: Chief Commercial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701